Results 61 to 70 of about 380,241 (292)

Diversity and complexity in neural organoids

FEBS Letters, EarlyView.
Neural organoid research aims to expand genetic diversity on one side and increase tissue complexity on the other. Chimeroids integrate multiple donor genomes within single organoids. Self‐organising multi‐identity organoids, exogenous cell seeding, or enforced assembly of region‐specific organoids contribute to tissue complexity.
Ilaria Chiaradia, Madeline A. Lancaster
wiley   +1 more source

Development of anti-PD-L1 antibody based on structure prediction of AlphaFold2

Frontiers in Immunology, 2023
Accurate structural information plays a crucial role in comprehending biological processes and designing drugs. Indeed, the remarkable precision of the AlphaFold2 has facilitated significant advancements in predicting molecular structures, encompassing ...
Kun Du, Kun Du, He Huang, He Huang
doaj   +1 more source

Moving forward to address key unanswered questions on targeting PD-1/PD-L1 in cancer: limitations in preclinical models and the need to incorporate human modifying factors. [PDF]

, 2019
The tremendous clinical success of immune checkpoint inhibition (ICI), particularly targeting the programmed cell death protein 1 (PD-1)/programmed death-ligand 1/2 (PD-L1/2) pathway, has resulted in application to multiple cancers, as a monotherapy and ...
Le, Catherine T, Murphy, William J
core   +1 more source

Linking neurogenesis, oligodendrogenesis, and myelination defects to neurodevelopmental disruption in primary mitochondrial disorders

FEBS Letters, EarlyView.
Mitochondrial remodeling shapes neural and glial lineage progression by matching metabolic supply with demand. Elevated OXPHOS supports differentiation and myelin formation, while myelin compaction lowers mitochondrial dependence, revealing mitochondria as key drivers of developmental energy adaptation.
Sahitya Ranjan Biswas, Porter L. Tomsick, Alicia M. Pickrell, Paul D. Morton   +3 more
wiley   +1 more source

PD-L1 diagnostic tests: a systematic literature review of scoring algorithms and test-validation metrics

Diagnostic Pathology, 2018
Background The programmed death receptor 1 (PD-1) protein is a cell-surface receptor on certain lymphocytes that, with its ligand programmed death ligand 1 (PD-L1), helps to down-regulate immune responses. Many cancer types express PD-L1 and evade immune
Margarita Udall, Maria Rizzo, Juliet Kenny, Jim Doherty, SueAnn Dahm, Paul Robbins, Eric Faulkner   +6 more
doaj   +1 more source

Flubendazole inhibits PD-1 and suppresses melanoma growth in immunocompetent mice

Journal of Translational Medicine, 2023
Background Immune checkpoint inhibitor therapy has revolutionized the clinical management of a diverse range of cancer types, including advanced cutaneous melanoma.
Yue Li, Ben Wu, Md Jakir Hossain, Lily Quagliata, Connor O’Meara, Marc R. Wilkins, Susan Corley, Levon M. Khachigian   +7 more
doaj   +1 more source

Scrambled Eggs: Apoptotic cell clearance by non-professional phagocytes in the Drosophila ovary [PDF]

, 2017
This manuscript was supported by NIH grant R01 GM060574 to KM.
McCall, Kimberly, Serizier, Sandy B.
core   +1 more source

The ubiquitin ligase RNF115 is required for the clearance of damaged lysosomes

FEBS Letters, EarlyView.
Upon lysosomal rupture, an E3 ubiquitin ligase RNF115 translocates from the cytosol to the damaged lysosomal membrane. Moreover, RNF115 depletion impairs the clearance of damaged lysosomes, identifying it as a key regulator of lysosomal quality control.
Sae Nakanaga, Toshiki Takahashi, Akiko Kuma, Hiroyuki Kawahara   +3 more
wiley   +1 more source

Programmed Cell Death Protein 1 (PD-1) and Programmed Cell Death Ligand 1 (PD-L1) Immunotherapy: A Promising Breakthrough in Cancer Therapeutics

Cureus, 2023
The advent of immune checkpoint inhibitors has revolutionized cancer therapy by leveraging the body's immune system to combat malignancies effectively. Among these groundbreaking agents, programmed cell death protein 1 (PD-1) and programmed cell death ligand 1 (PD-L1) inhibitors have emerged as pivotal therapeutic approaches.
Abaza, Abdelrahman, Sid Idris, Faten, Anis Shaikh, Humna, Vahora, Ilma, Moparthi, Kiran Prasad, Al Rushaidi, Majdah T, Muddam, Meghana Reddy, Obajeun, Omobolanle A, Jaramillo, Arturo P, Khan, Safeera   +9 more
openaire   +2 more sources

C2-Symmetrical Terphenyl Derivatives as Small Molecule Inhibitors of Programmed Cell Death 1/Programmed Death Ligand 1 Protein–Protein Interaction

Molecules
The PD-1/PD-L1 complex is an immune checkpoint responsible for regulating the natural immune response, but also allows tumors to escape immune surveillance. Inhibition of the PD-1/PD-L1 axis positively contributes to the efficacy of cancer treatment. The
Joanna Klimek, Oskar Kruc, Joanna Ceklarz, Beata Kamińska, Bogdan Musielak, Robin van der Straat, Alexander Dӧmling, Tad A. Holak, Damian Muszak, Justyna Kalinowska-Tłuścik, Łukasz Skalniak, Ewa Surmiak   +11 more
doaj   +1 more source